NASDAQ:MOR MorphoSys (MOR) Stock Price, News & Analysis $18.96 0.00 (0.00%) As of 10/1/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About MorphoSys Stock (NASDAQ:MOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MorphoSys alerts:Sign Up Key Stats Today's Range$18.96▼$18.9650-Day Range$18.96▼$18.9652-Week Range$4.18▼$19.50VolumeN/AAverage Volume1.02 million shsMarket Capitalization$2.86 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MorphoSys AG was a German biopharmaceutical company focused on discovering, developing and commercializing innovative antibody-based medicines for serious diseases, particularly cancer and autoimmune disorders. The company built its research programs around antibody technologies and developed products both independently and through collaborations with larger pharmaceutical companies. MorphoSys’s principal marketed products included Monjuvi in the United States and Minjuvi in Europe, an antibody therapy for certain adults with relapsed or refractory diffuse large B-cell lymphoma, developed in partnership with Incyte. Its earlier antibody discovery work also contributed to Tremfya, a treatment for inflammatory diseases developed and commercialized with Janssen Biotech. MorphoSys additionally advanced investigational medicines, including pelabresib, a therapy studied for myelofibrosis. Founded in 1992 and headquartered near Munich, Germany, MorphoSys served international markets through its own commercial operations and pharmaceutical partnerships. Jean-Paul Kress served as the company’s chief executive officer during its final years as an independent business. Novartis acquired MorphoSys in 2024, and the company subsequently ceased operating as an independent publicly traded entity.AI Generated. May Contain Errors. Read More Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MOR Stock News HeadlinesMorphosys AG : MORMay 31, 2026 | 247wallst.comNovartis notches another win for drug acquired in MorphoSys dealDecember 9, 2025 | finance.yahoo.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio.October 2 at 1:00 AM | Stansberry Research (Ad)Novartis' Avidity Deal: Growth Accretive, Multiple Gated By ExecutionOctober 27, 2025 | seekingalpha.comMyelofibrosis Market Overview: Epidemiology, Therapies, and Key Players include AbbVie, Morphosys, Geron, Bristol Myers Squibb, Kartos Therapeutics, Karyopharm Therapeutics, NS ...October 7, 2025 | theglobeandmail.comMaxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development OfficerJune 17, 2025 | finance.yahoo.comEssential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsightMarch 21, 2025 | theglobeandmail.comRoyalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receiptsFebruary 12, 2025 | seekingalpha.comSee More Headlines MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed this year? MorphoSys' stock was trading at $18.96 at the start of the year. Since then, MOR shares have increased by 0.0% and is now trading at $18.96. When did MorphoSys IPO? MorphoSys (MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers. How do I buy shares of MorphoSys? Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), e.l.f. Beauty (ELF), EMCOR Group (EME), Disc Medicine (IRON) and Builders FirstSource (BLDR). Company Calendar Today10/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MOR CIK1340243 Webwww.morphosys.com Phone(498) 989-9270Fax49-89-8992-7222Employees730Year Founded1992Profitability EPS (Trailing Twelve Months)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$205.35 million Net Margins-226.79% Pretax Margin-225.77% Return on Equity-694.31% Return on Assets-22.55% Debt Debt-to-Equity Ratio4.98 Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$238.28 million Price / Sales11.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book54.17Miscellaneous Outstanding Shares150,621,000Free Float150,546,000Market Cap$2.86 billion OptionableNot Optionable Beta1.20 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:MOR) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
